Get the latest news, insights, and market updates on APUS (Apimeds Pharmaceuticals US, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
MATAWAN, N.J. & MOSCOW, Idaho, November 10, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds") today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the h Nov 10, 2025 - $APUS
Apimeds Pharmaceuticals says "I love my Ducks" with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
MATAWAN, N.J. & EUGENE, Ore., October 14, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) ("Apimeds") today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboration with the University of Oregon’s Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the health Oct 14, 2025 - $APUS
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
MATAWAN, N.J., September 15, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds") today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego’s Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry. Sep 15, 2025 - $APUS
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
MATAWAN, N.J., September 12, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration’s (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company’s lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled "Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry", can be found here: https://www.fda.gov/regulatory-info Sep 12, 2025 - $APUS
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
MATAWAN, N.J., August 25, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds") today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business’s STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders. Aug 25, 2025 - $APUS
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
MATAWAN, N.J., July 15, 2025--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ("Apimeds" or the "Company"), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company’s proprietary ai²™ division. Jul 15, 2025 - $APUS
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Hopewell, New Jersey, May 12, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the closing of its initial public offering (the “Offering”) of 3,375,000 shares of common stock at a public offering price of $4.00 per share. The s May 12, 2025 - $APUS
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Hopewell, New Jersey, May 08, 2025 (GLOBE NEWSWIRE) -- Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects, today announced the pricing of its initial public offering of 3,375,000 shares of common stock at a price of $4.00 per share. The gross proceeds to Apimeds from the May 8, 2025 - $APUS
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple